The annual meeting of DSKO 2014 preliminary program Hotel Nyborg Strand, the 27 th 29 th of March 2014

Transcription

1 The annual meeting of DSKO 2014 preliminary program Hotel Nyborg Strand, the 27 th 29 th of March 2014 Thursday Registration and coffee Hypofractionation in radiotherapy for breast and prostate cancer are we making progress or is history repeating itself? Introduction Nicolaj Andreassen, Aarhus Universitetshospital & Ivan Vogelius, Rigshospitalet The long and the short of breast cancer hypofractionation John Yarnold, Institute of Cancer Research, London, UK Hypofractionation in prostate cancer Morten Høyer, Aarhus Universitetshospital Break Panel discussion Dinner 20.30? Generalforsamling DSKO (auditoriet) Efter DSKO s generalforsamling afholdes sideløbende generalforsamlinger i FYO (auditoriet) og DKOO (salon ).

2 07.00? Morning run 5 km Registration Approval of new anti-cancer agents in Denmark: Regulations and Procedures Chairman: Morten Mau Sørensen, Rigshospitalet Introduction Morten Mau Sørensen, Rigshospitalet Poll: The opinion of the participants in the annual meeting of DSKO Annual cost of anti-cancer agents in DK: in the past, present and the future. Implications from Amgros and RADS. Merete Chur Fischer & Bente Dam, Amgros The mechanism of approval of new anti-cancer drugs in the EU: What are the criteria for approval? Jens Ersbøll, Danish National Board of Health Procedures for national approval of new and expensive anticancer agents in Denmark as standard treatment: What is KRIS, how does KRIS work, and what are the criteria for approval for national use? Steen Werner Hansen, Coordination Council for the use of Hospital Medicine under the Danish Regions (KRIS) Coffee break Perspectives on European regulatory and health technology assessment of new cancer drugs: Similarities and differences and possible implications for clinical outcome Lothar Bergmann, University Hospital of Frankfurt, Germany

3 Presentation of pivotal clinical data for drugs that have been evaluated by KRIS: How strong is the clinical evidence for real clinical benefit? Abiraterone v/ Henriette Lindberg, Herlev Hospital Regorafenib and Aflibercept v/ Per Pfeiffer, Odense Universitetshospital Exemestan + Everolimus v/ Bent Ejlertsen, Rigshospitalet Panel discussion Poll Concluding remarks Morten Mau Sørensen, Rigshospitalet Lunch DSKO s Onkologipris Coffee break Oral abstract session Bedømmere: Cai Grau, Aarhus Universitetshospital & Jesper Grau Eriksen, Odense Universitetshospital Introduction Long term results of a randomized trial in locally advanced rectal cancer: No benefit from adding a brachytherapy boost Ane L Appelt, Vejle Sygehus A new procedure fore sampling fine needle aspirations enables isolation of high quality mrna Birgitte Sandfeld Paulsen, Århus Universitetshospital

4 A cross-sectional study of morbidity after axillary lymph node dissection, adjuvant taxane based chemotherapy and axillary radiotherapy in breast cancer Rasmus Blechingberg Friis, Århus Universitetshospital CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab Kristin Skougaard, Herlev Hospital PAI-1 as prognostic marker in patients with colorectal cancer Kristoffer Staal Rohrberg, Rigshopitalet Old age and poor prognosis increase the likelihood of disagreement between cancer patients and their oncologists on the indication for resuscitation attempt Lena Saltbaek, Herlev Hospital Hall D + E Poster session and bar Vandrehallen Velkomst drink Sal J + I + H Middag og dans

5 Saturday Sikken en fest Et par milliarder senere Hvad fik vi for pengene? Chairman: Niels Holm, Odense Universitetshospital Indledning Niels Holm, Odense Universitetshospital Status for kræftområdet 2014 Jens Overgaard, Aarhus Universitetshospital Kræftpakkerne: Har de virket? Peter Vedsted, Aarhus Universitet Kaffepause Hvordan synes vi selv, det går? Lisa Sengeløv, Herlev Hospital milliarder kr. senere, har vi fået noget for pengene? Jakob Kjellberg, KORA Paneldiskussion